Are we prepared to deal with the Alzheimer's disease pandemic

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 4, 2010, Pages 563-565

  Holtzman, J L ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ESTROGEN; FENYRAMIDOL; GESTAGEN; IBUTAMOREN; PRESENILIN 1; PRESENILIN 2; TARENFLURBIL; ALZHEIMER DISEASE VACCINE; FLURBIPROFEN;

ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG EFFICACY; GENETIC TRANSFECTION; GINKGO BILOBA; HEALTH CARE COST; HUMAN; PANDEMIC; PRIORITY JOURNAL; REVIEW; SOCIETY; TREATMENT FAILURE; VERY ELDERLY; AGING; ANIMAL; EPIDEMIC; GENETICS; METABOLISM; MOUSE; PATHOLOGY; TRANSGENIC MOUSE; UNITED STATES;

AGING; ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PROTEIN; ANIMALS; DISEASE OUTBREAKS; FLURBIPROFEN; HUMANS; MICE; MICE, TRANSGENIC; PRESENILIN-1; UNITED STATES; AMYLOID BETA-PEPTIDES;

EID: 77957020887     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.84     Document Type: Review

References (26)

1. Green, R.C. et al.; Tarenflurbil Phase 3 Study Group. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 302, 2557-2564 (2009).
2. Masters, C.L., Simms, G., Weinman, N.A., Multhaup, G., McDonald, B.L. & Beyreuther, K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. U.S.A. 82, 4245-4249 (1985).
3. Selkoe, D.J. Translating cell biology into therapeutic advances in Alzheimers disease. Nature 399, A23-A31 (1999).
4. Holtzman, J.L. The failure of the APP transgenic mouse models to predict efficacy of agents in clinical trials of Alzheimers disease: these findings suggest that there is a need for a new paradigm for drug development. In Research Progress in Alzheimers Disease and Dementia Vol. 4 (ed. M.-K. Sun) Ch 5, 113-144 (Nova Science, New York, 2009).
5. C Leary, J.P. et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 8, 79-84 (2005).
6. Katzman, R. et al. Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann. Neurol. 23, 138-144 (1988).
7. Giannakopoulos, P., Hof, P.R., Michel, J.P., Guimon, J. & Bouras, C. Cerebral cortex pathology in aging and Alzheimers disease: a quantitative survey of large hospital-based geriatric and psychiatric cohorts. Brain Res. Brain Res. Rev. 25, 217-245 (1997).
8. Wolf, D.S., Gearing, M., Snowdon, D.A., Mori, H., Markesbery, W.R. & Mirra, S.S. Progression of regional neuropathology in Alzheimer disease and normal elderly: findings from the Nun study. Alzheimer Dis. Assoc. Disord. 13, 226-231 (1999).
9. Bennett, D.A. et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 66, 1837-1844 (2006).
10. Savva, G.M., Wharton, S.B., Ince, P.G., Forster, G., Matthews, F.E. & Brayne, C .; Medical Research Council Cognitive Function and Ageing Study. Age, neuropathology, and dementia. N. Engl. J. Med. 360, 2302-2309 (2009).
11. Bertram, L. & Tanzi, R.E. Genome-wide association studies in Alzheimers disease. Hum. Mol. Genet. 18, R137-R145 (2009).
12. Herzog, V., Kirfel, G., Siemes, C. & Schmitz, A. Biological roles of APP in the epidermis. Eur. J. Cell Biol. 83, 613-624 (2004).
13. Brouwers, N., Sleegers, K. & Van Broeckhoven, C. Molecular genetics of Alzheimers disease: an update. Ann. Med. 40, 562-583 (2008).
14. Nikolaev, A., McLaughlin, T., OLeary, D.D. & Tessier-Lavigne, M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 457, 981-989 (2009).
15. Hass, M.R., Sato, C., Kopan, R. & Zhao, G. Presenilin: RIP and beyond. Semin. Cell Dev. Biol. 20, 201-210 (2009).
16. Holmes, C. et al. Long-term effects of Abeta42 immunisation in Alzheimers disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372, 216-223 (2008).
17. Sevigny, J.J., Ryan, J.M., van Dyck, C.H., Peng, Y., Lines, C.R. & Nessly, M.L.; MK-677 Protocol 30 Study Group. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology 71, 1702-1708 (2008).
18. DeKosky, S.T. et al.; Ginkgo Evaluation of Memory (GEM) Study Investigators. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 300, 2253-2262 (2008).
19. Espeland, M.A. et al.; Womens Health Initiative Memory Study. Conjugated equine estrogens and global cognitive function in postmenopausal women: Womens Health Initiative Memory Study. JAMA 291, 2959-2968 (2004).
20. Erickson, R.R. et al. In cerebrospinal fluid ER chaperones ERp57 and calreticulin bind beta-amyloid. Biochem. Biophys. Res. Commun. 332, 50-57 (2005).
21. Erickson, R.R., Dunning, L.M. & Holtzman, J.L. The effect of aging on the chaperone concentrations in the hepatic, endoplasmic reticulum of male rats: the possible role of protein misfolding due to the loss of chaperones in the decline in physiological function seen with age. J. Gerontol. A Biol. Sci. Med. Sci. 61, 435-443 (2006).
22. Holtzman, J.L. The roles of the thiol:protein disulfide oxidoreductases in membrane and secretory protein synthesis within the lumen of the endoplasmic reticulum. J. Investig. Med. 45, 28-34 (1997).
23. Vembar, S.S. & Brodsky, J.L. One step at a time: endoplasmic reticulumassociated degradation. Nat. Rev. Mol. Cell Biol. 9, 944-957 (2008).
24. Seabrook, G.R., Ray, W.J., Shearman, M. & Hutton, M. Beyond amyloid: the next generation of Alzheimers disease therapeutics. Mol. Interv. 7, 261-270 (2007).
25. Frisardi, V. et al. Towards disease-modifying treatment of Alzheimers disease: drugs targeting beta-amyloid. Curr. Alzheimer Res. 7, 40-55 (2010).
26. Nicoll, J.A.R., Boche, D. and Holmes, C. Amyloid-β vaccination for Alzheimers dementia-authors reply. Lancet 372, 1381-1382 (2008).